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Background: Although adjuvant gemcitabine (GEM) chemotherapy for pancreatic cancer is standard, the quality of
life (QOL) in those patients is still impaired by the standard regimen of GEM. Therefore, we studied whether mild
dose-intensity adjuvant chemotherapy with bi-weekly GEM administration could provide a survival benefit with
acceptable QOL to the patients with pancreatic cancer.
Methods: After a phase I trial, an adjuvant bi-weekly 1,000 mg/m2 of GEM chemotherapy was performed in 58
patients with pancreatic cancer for at least 12 courses (Group A). In contrast, 36 patients who declined the adjuvant
bi-weekly GEM chemotherapy underwent traditional adjuvant 5FU-based chemotherapy (Group B). Careful
periodical follow-ups for side effects of GEM and disease recurrence, and assessment of patients’ QOL using the
EORTC QOL questionnaire (QLQ-C30) and pancreatic cancer-specific supplemental module (QLQ-PAN26) were
performed. Retrospectively, the degree of side effects, patients’ QOL, compliance rate, disease-free survival (DFS),
and overall survival (OS) in Group A were compared with those in Group B.
Results: No severe side effects (higher than Grade 2 according to the common toxicity criteria of ECOG) were
observed, except for patients in Group B, who were switched to the standard GEM chemotherapy. Patients’ QOL
was better in Group A than B (fatigue: 48.9 ± 32.1 versus 68.1 ± 36.3, nausea and vomiting: 26.8 ± 20.4 versus 53.7
± 32.6, diarrhea: 21.0 ± 22.6 versus 53.9 ± 38.5, difficulty gaining weight: 49.5 ± 34.4 versus 67.7 ± 40.5, P < 0.05).
Compliance rates in Groups A and B were 93% and 47%. There was a significant difference in the median DFS
between both groups (Group A : B =12.5 : 6.6 months, P < 0.001). The median OS of Group A was prolonged
markedly compared with Group B (20.2 versus 11.9 months, P < 0.005). For OS between both groups, univariate
analysis revealed no statistical difference in 69-year-old or under females, and T1–2 factors, moreover, multivariate
analysis indicated three factors, such as bi-weekly adjuvant GEM chemotherapy, T2 or less, and R0.
Conclusions: Adjuvant chemotherapy with bi-weekly GEM offered not only the advantage of survival benefits but
the excellent compliance with acceptable QOL for postoperative pancreatic cancer patients.
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Pancreatic cancer is increasing rapidly worldwide and
the prognosis is still quite poor even if the patient
undergoes curative resection [1]. Compared to conven-
tional 5-fluorouracil (5FU)-based chemotherapies [2],
gemcitabine (GEM) showed improved prognosis of
patients with non-resectable advanced pancreatic cancer
in a randomized trial [3]. Subsequently, studies on adju-
vant chemotherapy with 5FU and/or GEM for patients
with resectable pancreatic cancer have been reported
[4-9].
Thereafter, in our institution, adjuvant GEM chemo-
therapy with the standard regimen for patients with re-
sectable pancreatic cancer had been used from 2001 to
2003. However, the compliance rate was very low, 38%,
due to severe side effects, such as gastrointestinal dis-
comforts and emaciation, even though the adjuvant
chemotherapy was adjusted according to the reduction
and extension criteria. The majority of pancreatic cancer
patients, over 40 cases, failed to continue the adjuvant
GEM chemotherapy with the standard regimen, and
died without obtaining the beneficial effects of GEM.
From the bitter experience of the low compliance rate in
our institution, we hypothesized that the dose intensity
of adjuvant GEM chemotherapy with the standard regi-
men was too heavy and harmful for people
of Asian descent, and a milder dose-intensity of adju-
vant GEM chemotherapy with bi-weekly administration
might be more suitable and lead to prolongation of DFS
and/or OS without impairing patients’ QOL.
Thereby, after a phase I study, we studied whether
mild dose-intensity adjuvant chemotherapy with bi-
weekly GEM administration could provide prolonged
disease-free survival (DFS) and/or overall survival (OS)
without impairing patients’ quality of life (QOL).
Methods
After approval from the IRB (the ethics committee for
biomedical research) in our university, a phase I study of
adjuvant bi-weekly GEM chemotherapy was conducted
in our institute using three different doses: a high dose
(1,200 mg/m2), a medium dose (1,000 mg/m2), and a
low dose (800 mg/m2). Each dose group consisted of at
least six patients; the compliance rate in the high dose
group was low, 47%, while the rates in the middle and
low dose groups were 96% and 97%. Moreover, there
was no significant difference in the side effects between
the middle and low dose groups according to the com-
mon toxicity criteria of the ECOG. Consequently, the
appropriate dose-intensity of adjuvant bi-weekly GEM
chemotherapy was set at 1,000 mg/m2 in our institute.
During a five-year period between 2004 and 2009, 128
patients with ductal pancreatic carcinomas were treated
with surgery in our institution. A clinical study of milddose-intensity, adjuvant bi-weekly GEM chemotherapy
was performed with a total of 58 pancreatic cancer
patients (Group A), who gave informed consent (IC). On
the other hand, 36 patients (Group B), who did not give
IC for adjuvant bi-weekly GEM chemotherapy, chose
5FU-based chemotherapy as the traditional adjuvant
treatment. The remaining 34 patients were excluded
from this study due to: macroscopic non-curative surgi-
cal treatment (22 cases), previous treatment of the
current disease with more than one chemotherapeutic
regimen and/or radiotherapy (3 cases), major complica-
tions after surgery such as aspiration pneumonia and/or
leakage of pancreatojejunostomy (2 cases), hospital death
after aggressive progression of the disease (1 case), not
less than 85 years old (1 case), not providing IC for adju-
vant chemotherapy (1 case), and physical conditions: ac-
tive infection (1 case), interstitial pneumonia or pulmonary
fibrosis (1 case), myocardial infarction within 3 months
(1 case), and concomitant advanced cancer (1 case).
In Group A, the first administration of 1,000 mg/m2 of
GEM was given during the third week after surgery, that
is, 15–21 postoperative days (POD) if the patient’s con-
dition was favorable. One cycle of this regimen was
defined as twice bi-weekly administrations of GEM.
After discharge from our hospital, administration of
1,000 mg/m2 of GEM was given consecutively to the
outpatients at bi-weekly intervals, for at least six full
cycles or until the patient’s condition was considered tol-
erable. If severe side effects occurred, the 1,000 mg/m2
dosage of GEM was reduced to 800 mg/m2. These
severe side effects were: leukopenia <1,000 / mm-3, de-
creasing platelets <20,000 / mm-3, neutrophils <1,000 /
mm-3 with fever (>38°C) or infection, and non-he-
matologic toxicity higher than Grade 3 according to the
common toxicity criteria of the ECOG except for gastro-
intestinal toxicity, such as nausea, vomiting, diarrhea,
and stomatitis. Additionally, when there were multiple
side effects, the administration of GEM was extended
until the patient’s recovery. If recovery needed more
than two weeks, the study was discontinued. The mul-
tiple side effects were: leukopenia <2,000 / mm-3, de-
creasing platelets <70,000 / mm-3, and non-hematologic
toxicity higher than Grade 2 according to the common
toxicity criteria of the ECOG except for gastroint-
estinal toxicity, such as nausea, vomiting, diarrhea, and
stomatitis.
In Group B, the postoperative patients were treated
with adjuvant 5FU-based chemotherapy consisting of an
intravenous 20 mg/m2 bolus of leucovorin followed by
an intravenous 400 mg/m2 bolus of fluorouracil given on
each 5 consecutive days every 28 days for 6 cycles. The
adjuvant 5FU-based chemotherapy was also started dur-
ing the third week after surgery, the same as Group A.
When recurrence was identified in Group B, the adjuvant
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GEM administration (1,000 mg/m2 on days 1, 8, and 15,
repeated every four weeks for a total of at least six
courses) as for the patients who had agreed with the ther-
apy alteration.
The patients in both groups were followed up care-
fully, especially for side effects from the agents, disease
recurrence, and the patients’ QOL, as measured accord-
ing to the European Organisation for Research and
Treatment of Cancer’s (EORTC) quality of life question-
naire (quality of life questionnaire – core 30 or QLQ-
C30) and the pancreatic cancer-specific supplemental
module (quality of life questionnaire – pancreatic cancer
module 26 or QLQ-PAN26) [10-13]. The assessment of
patients’ QOL in both groups was carried out at each
outpatient appointment. Postoperative surveillance forTable 1 Characteristics of eligible patients






























a Pancreatoduodenectomy, b distal pancreatectomy, c R0 or R1 means negative or positivethe recurrence of pancreatic cancer was undertaken
every three months.
Thus, the 58 cases in Group A were compared to the 36
cases in Group B retrospectively. Statistical analysis was
performed using student’s t-test, the chi-square test, the
Mann–Whitney test, the log-rank test, the Kaplan–Meier
method, and the Cox hazard proportional model. Results
were considered to be statistically significant when P < 0.05.
Results
The patients’ ages in Group A ranged from 34 to 82
(median 68.0) years, the patients’ other characteristics
such as sex, operative procedure, primary tumor size,
nodal status, resection status, and the UICC’s TNM clas-
sification [14] are displayed in Table 1. Of the patients in






















margin microscopically, d sixth edition of International Union Against Cancer stages.
Table 2 Assessment of patients’ quality of life
Group A (n = 58) Group B (n = 36) P value
Functional scales, mean ± SD
Physical status 69.5 ± 31.3 67.8 ± 33.4 NS
Working ability 58.6 ± 40.1 55.4 ± 42.2 NS
Cognitive functioning 67.5 ± 34.8 66.1 ± 36.6 NS
Emotional functioning 62.3 ± 38.6 59.4 ± 28.5 NS
Social functioning 58.1 ± 32.5 53.3 ± 39.7 NS
Global quality of life 61.9 ± 33.3 51.7 ± 37.0 NS
Symptom scales, mean ± SD
Fatigue 48.9 ± 32.1 68.1 ± 36.3 P < 0.05
Nausea and vomiting 26.8 ± 20.4 53.7 ± 32.6 P < 0.05
Pain 36.2 ± 28.5 34.2 ± 30.9 NS
Dyspnea 22.0 ± 27.9 32.2 ± 22.8 NS
Insomnia 55.7 ± 38.7 61.1 ± 41.7 NS
Appetite loss 33.3 ± 36.1 43.3 ± 39.1 NS
Constipation 23.8 ± 31.8 26.4 ± 30.4 NS
Diarrhea 21.0 ± 22.6 53.9 ± 38.5 P < 0.05
Financial difficulties 52.3 ± 37.3 58.8 ± 40.4 NS
Pancreas-specific pain 44.4 ± 29.2 49.5 ± 36.6 NS
Diet restriction 42.5 ± 32.0 54.1 ± 37.8 NS
Jaundice and pruritus 12.7 ± 20.1 18.8 ± 19.9 NS
Steatorrhea 36.1 ± 30.4 39.1 ± 34.7 NS
Poor body image 38.3 ± 34.2 59.8 ± 35.0 NS
Sexual dysfunction 66.8 ± 35.8 75.3 ± 41.1 NS
Dissatisfaction with care 61.2 ± 37.7 65.6 ± 39.1 NS
Bloating 41.7 ± 31.5 49.7 ± 37.4 NS
Bad-tasting food 29.4 ± 36.9 37.4 ± 38.2 NS
Indigestion 30.7 ± 30.1 39.5 ± 28.6 NS
Flatulence 35.7 ± 31.5 38.0 ± 32.3 NS
Difficulty gaining weight 49.5 ± 34.4 67.7 ± 40.5 P < 0.05
Weakness 45.9 ± 32.8 56.6 ± 42.7 NS
Dry mouth 40.5 ± 38.0 49.1 ± 36.9 NS
Treatment side-effects 39.1 ± 30.5 46.2 ± 33.8 NS
Worry about future 57.8 ± 35.8 66.3 ± 27.6 NS
Difficulty planning 34.6 ± 33.7 46.8 ± 45.2 NS
SD standard deviation; NS no significant difference.
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GEM, although the other four patients needed an occa-
sional extension of administration interval from bi- to
tri-weekly, not because of hematologic toxicity but be-
cause of their suboptimal physical status.
The patients’ age in Group B varied from 50 to 84
(median 69.5) years and the patients’ other characte-
ristics are also indicated in Table 1. There were no
statistical differences between both groups in the charac-
teristics of the eligible patients. Except when during theimplementation of the standard GEM administration
as the second line of chemotherapy for the patients
with recurrence disease in Group B, no severe side
effects (higher than Grade 2 according to the com-
mon toxicity criteria of the ECOG) were observed.
Ultimately, 30 cases of the 36 patients in Group B
(83.3%) were converted from traditional 5FU-based
chemotherapy to GEM administration with the stan-
dard regimen due to the recurrence of pancreatic
cancer.
Figure 1 Disease-free survival (DFS) of resected pancreatic
cancer patients who received adjuvant chemotherapy with bi-
weekly gemcitabine (GEM: Group A) versus 5FU-based (5FU:
Group B). mo., months (Log-rank test P < 0.001).
Figure 3 Comparison of overall survival (OS) for resected
pancreatic cancer patients between bi-weekly gemcitabine
(GEM: Group A) and 5FU-based (5FU: Group B) in Stage 0–IIa.
mo., months (Log-rank test P< 0.01).
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tinuously the second line of standard GEM chemother-
apy until they collapsed; accordingly, the compliance
rate of the standard GEM chemotherapy in this study
was low, 36.7% (11/30). Consequently, the total compli-
ance rate in Group B was 47.2% (17/36). Compared with
the low compliance rate in Group B, most of the
patients in Group A continuously received the adjuvant
bi-weekly GEM chemotherapy with a 93% (54/58) com-
pliance rate until their acceptable physical status.
The QOL of patients in Group A was immensely bet-
ter than that of patients in Group B, in which most of
the patients converted to the standard GEM chemother-
apy (P < 0.05), especially for fatigue, nausea and vomit-
ing, diarrhea, and difficulty gaining weight in the
symptom scales (Table 2).
The median DFS of Group A was significantly
improved in contrast with Group B (12.5 versus 6.6
months, P < 0.001, Figure 1). As shown in Figure 2, each
median OS was 20.2 months in Group A versus 11.9
months in Group B, and each three-year OS rate wasFigure 2 Overall survival (OS) of resected pancreatic cancer
patients who received adjuvant chemotherapy with bi-weekly
gemcitabine (GEM: Group A) versus 5FU-based (5FU: Group B).
mo., months (Log-rank test P< 0.005).24.0% in Group A versus 4.8% in Group B, suggesting
that there was a significant difference between the two
groups statistically (P < 0.005). When OS for patients at
Stages 0–IIa and IIb–IV is compared between Groups A
and B, a statistical difference was observed in each of
the classified stages (Figures 3 and 4). The median sur-
vival of living patients was 52.1 months in Group A (n =
7) versus 28.7 months in Group B (n = 2). The longest
survival time in Group A was over 6.7 years (80.4
months) while for Group B it was over 3.0 years (36.1
months). However, for the other patients, 51 in Group A
and 34 in Group B died of recurrences of pancreatic
cancer due to peritonitis carcinomatosa or multiple dis-
tant metastases in the liver, bone, and/or lung.
Univariate analysis for the subgroups in Table 3
showed that there were no statistical differences between
the groups for 69-year-old or under females and T1–2
factors. As shown in Table 4, multivariate analysis for
OS in both groups indicated three statistically important
factors: bi-weekly adjuvant GEM chemotherapy, T2 or
less, and R0.Figure 4 Comparison of overall survival (OS) for resected
pancreatic cancer patients between bi-weekly gemcitabine
(GEM: Group A) and 5FU-based (5FU: Group B) in Stage IIb–IV.
mo., months (Log-rank test P< 0.05).




A B A B P value
All patients 58 36 20.2 11.9 0.001
Age ≦69 38 20 19.7 12.9 0.061 NS
>70 20 16 20.4 8.6 0.001
Sex: male 36 20 20.4 6.3 0.001
Sex: female 22 16 19.8 12.6 0.094 NS
T1–2 11 9 36.6 20.5 0.086 NS
T3–4 47 27 15.6 9.4 0.000
N0 27 15 21.3 13.0 0.007
N1 31 21 13.6 7.0 0.017
R0 43 28 20.7 12.5 0.001
R1 15 8 13.4 5.5 0.034
Stage 0–IIA 29 13 23.7 15.4 0.008
Stage IIB–IV 29 23 13.4 7.0 0.043
NS no significant difference.
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Several successful clinical trials of adjuvant chemother-
apy based on 5FU and/or GEM for pancreatic cancer
have been published [15-25]. Moreover, recent prospect-
ive, randomized studies of adjuvant GEM chemotherapy
suggested an improvement in DFS and/or OS of pancre-
atic cancer patients [26-31], except for the ESPAC-3 trial
[32]. Thus, adjuvant chemotherapy using GEM for pan-
creatic cancer has been recognized as an effective treat-
ment. Although it was an adjuvant GEM trial, CONKO-
001 indicated prolonged OS of pancreatic cancer patients
and unsatisfied compliance (less than 62%) of GEM ad-
ministration with the standard regimen was also reported
[26]. In general, it has been thought that the main purpose
of adjuvant chemotherapy is prolongation of DFS and/or
OS by preventing or delaying disease relapse without
impairing patients’ QOL. Previously, we had experienced
that GEM administration with the standard regimen led
to an unsatisfied compliance rate of 38% for pancreaticTable 4 Multivariate analysis for overall survival
HR (95% CI) P value
Treatment with GEM 0.34 (0.20–0.57) 0.0001a
Age <70 1.09 (0.68–1.77) 0.7104
Male 0.89 (0.53–1.48) 0.6490
T factor ≦T2 0.49 (0.25–0.94) 0.0314a
N factor N0 0.75 (0.26–2.19) 0.6046
UICC stage ≦VIIA 1.23 (0.36–4.26) 0.7415
Resection status R0 0.38 (0.20–0.73) 0.0033a
aStatistically significant difference.
CI confidence interval; GEM gemcitabine; HR hazard ratio.cancer patients after surgery. The patients suffered from
severe side effects (over Grade 3) and had reduced QOL.
Thus, the compliance rate generally seemed to be intim-
ately correlated with patients’ QOL. Therefore, in terms of
reducing toxicity, increasing compliance rate, and obtain-
ing acceptable QOL, a phase I study was carried out in
our department to determine an optimal dose-intensity of
adjuvant GEM chemotherapy. After the phase I trial, in
which the optimal dose-intensity was set at bi-weekly
1,000 mg/m2 of GEM administration, this trial studied
whether the optimal, medium dose-intensity adjuvant bi-
weekly GEM chemotherapy for pancreatic cancer patients
would obtain both prolongation of OS and satisfactory
compliance, that is, the patients’ QOL was studied to see
if it was acceptable.
Results from this clinical study suggest that the adju-
vant bi-weekly chemotherapy with 1,000 mg/m2 of GEM
(Group A) statistically prolonged DFS and OS for pan-
creatic cancer patients when compared with the adju-
vant 5FU-based chemotherapy (Group B) as a whole and
in Stage 0–IIa and Stage IIb–IV subgroups. Thus, the
adjuvant bi-weekly GEM chemotherapy was more effect-
ive than the 5FU-based treatment in resected pancreatic
cancer patients even though most patients in Group B
converted to the standard GEM chemotherapy due to
the recurrence of pancreatic cancer. Previously, it had
been reported in a Norwegian randomized study [2],
ESPAC-1, and other trials [7-9,15,16] that adjuvant che-
motherapies using 5FU for resectable pancreatic cancer
led to significant survival benefit. On the other hand,
results from a phase III trial conducted by the EORTC
on the gastrointestinal tract cancer cooperative group
and two Japanese adjuvant chemotherapy studies indi-
cated that 5FU could not achieve such a survival advan-
tage [5,33,34]. The RTOG 97–04 study indicated that
GEM was superior to 5FU as an adjuvant chemora-
diotherapy agent [27,28]. Results from this study also
supported the potency of GEM compared to 5FU. The
compliance rate of Group A in this study was higher
than that of CONKO-001 study [26] in which GEM was
given with the standard regimen (93% versus 62%).
According to EORTC QLQ-C30 and QLQ-PAN26, the
QOL of patients in Group A was much better than that
of Group B, suggesting that our administration rate and
dosage of GEM, that is, the medium dose-intensity, were
tolerable and applicable even to patients with pancreatic
cancer following major surgery. The results of the uni-
variate analysis shown in Table 3 implied that the malig-
nancy potential of the tumors was stronger in the
younger generation, the effectiveness of gemcitabine was
less in females than males, and for smaller tumors the
surgical treatment had a greater affect than adjuvant
chemotherapy. The multivariate analysis shown in Table 4
suggested that early detection of pancreatic cancer, good
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GEM were important to obtain a prolonged OS, such as
that for the previous standard of GEM chemotherapy.
Currently, combination chemotherapy of GEM with
new agents, such as capecitabine, erlotinib, or bevacizu-
mab, has been used to try to improve the poor survival
rate of patients with advanced pancreatic cancer [35-41].
More recently, combination therapies using peptide vac-
cines with GEM, which have achieved striking tumor
reduction in advanced pancreatic cancer patients, have
been reported [42-46]. Nowadays, ongoing adjuvant che-
motherapy trials, such as JASPAC-01 (GEM versus S-1),
ESPAC-4 (GEM versus GEM+capecitabine), CONKO-005
(GEM versus GEM+erlotinib), and CONKO-006 (GEM
versus GEM+sorafenib) are under trial [47-54]. These new
approaches may be able to obtain better prognosis in
patients after curative resection of pancreatic cancer. How-
ever, it seems likely that good QOL is as important a fac-
tor for resected pancreatic cancer patients as prolongation
of OS.
Conclusions
In conclusion, the medium dose-intensity adjuvant chemo-
therapy with bi-weekly GEM led to improved OS with ac-
ceptable QOL in pancreatic cancer patients after surgery.
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